Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4

Life Sciences

Volumn 67, Issue 25, 2000, Pages 3103-3112

  Chan, William K ^a   Delucchi, Anthony B ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

Cytochrome P450 3A4; Mechanism based inhibition; Red wine; Resveratrol

Indexed keywords

CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; ENZYME INHIBITOR; MIXED FUNCTION OXIDASE; RESVERATROL; STILBENE DERIVATIVE;

ANIMAL; ARMYWORM; ARTICLE; DRUG ANTAGONISM; HUMAN; KINETICS; WINE;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; KINETICS; MIXED FUNCTION OXYGENASES; SPODOPTERA; STILBENES; WINE;

EID: 0034634252     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(00)00888-2     Document Type: Article

References (29)

1. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? And gone? Clin. Biochem. 1997; 30(2): 91-113.
2. Fremont L. Biological effects of resveratrol. Life Sci. 2000; 66 (8): 663-73.
3. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275 (5297): 218-20.
4. Gehm BD, McAndrews JM, Chien PY, Jameson JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. USA 1997; 94 (25): 14138-43.
5. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin. Chim. Acta 1995; 235 (2): 207-19.
6. Goldberg DM, Hahn SE, Parkes JG. Beyond alcohol: beverage consumption and cardiovascular mortality. Clin. Chim. Acta 1995; 237 (1-2): 155-87.
7. Subbaramaiah K, Michaluart P, Chung WJ, Tanabe T, Telang N, Dannenberg AJ. Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Ann. N. Y. Acad. Sci. 1999; 889: 214-23.
8. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM, Dannenberg AJ. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem. 1998; 273 (34): 21875-82.
9. Chun YJ, Kim MY, Guengerich FP. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem. Biophys. Res. Commun. 1999; 262 (1): 20-4.
10. Ciolino HP, Daschner PJ, Yeh GC. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res. 1998; 58 (24): 5707-12.
11. Teel RW, Huynh H. Modulation by phytochemicals of cytochrome P450-linked enzyme activity. Cancer Lett. 1998; 133(2): 135-41.
12. Casper RF, Quesne M, Rogers IM, Shirota T, Jolivet A, Milgrom E, Savouret JF. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol. Pharmacol. 1999; 56 (4): 784-90.
13. Chan WK, Nguyen LT, Miller VP, Harris RZ. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci. 1998; 62 (10): L135-42.
14. Ortiz de Montellano PR, Correia MA. Inhibition of cytochrome P450 enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450: Structure, Mechanism, and Biochemistry. New York: Plenum Press, 1995. pp. 305-64.
15. Sahali-Sahly Y, Balani SK, Lin JH, Baillie TA. In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4. Chem. Res. Toxicol. 1996; 9(6): 1007-12.
16. Lee CA, Kadwell SH, Kost TA, Serabjit-Singh CJ. CYP3A4 ex pressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4. Arch. Biochem. Biophys. 1995; 319 (1): 157-67.
17. Kitz R, Wilson IB. Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J. Biol. Chem. 1962; 237: 3245-9.
18. Larrey D, Funck-Brentano C, Breil P, Vitaux J, Theodore C, Babany G, Pessayre D. Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochem. Pharmacol. 1983; 32 (6): 1063-8.
19. Pessayre D, Larrey D, Vitaux J, Breil P, Belghiti J, Benhamou JP. Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans. Biochem. Pharmacol. 1982; 31 (9): 1699-704.
20. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 1992; 90 (5): 1871-8.
21. Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, Mayo RR, Turgeon DK, Bailey DG, Fontana RJ, Wrighton SA. Molecular and physical mechanisms of first-pass extraction. Drug Metab. Dispos. 1999; 27 (2): 161-6.
22. Chun YJ, Kim MY, Guengerich FP. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem. Biophys. Res. Commun. 1999; 262 (1): 20-24.
23. He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem. Res. Toxicol. 1998; 11 (4): 252-9.
24. Shou M, Mei Q, Ettore MW, Jr., Dai R, Baillie TA, Rushmore TH. Sigmoidal kinetic mode for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem. J. 1999; 340 (Pt 3): 845-53.
25. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, Tracy TS. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 1998; 37 (12): 4137-47.
26. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations [see comments]. Clin. Pharmacol. Ther. 1998; 64 (2): 177-82.
27. Bailey DG, Bend JR, Arnold JM, Tran LT, Spence JD. Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin. Pharmacol. Ther. 1996; 60 (1): 25-33.
28. Offman EM, Freeman DJ, DrEsser GK, Bend JR, Munoz C, Bailey DG. Cisapride interaction with grapefruit juice and red wine. Clin. Pharmacol. Ther. 2000; 67 110.
29. Tsunoda SM, Harris RZ, Velez RL, Warshaw A, PA-C, Freeman RB. Red wine effects on cyclosporine pharmacokinetics. Clin. Pharmacol. Ther. 1999; 65(2): 159.